Inherited platelet disorders: Thrombocytopenias and thrombocytopathies

Blood Transfusion

Volumn 7, Issue 4, 2009, Pages 278-292

  D'Andrea, Giovanna ^a   Chetta, Massimiliano ^a   Margaglione, Maurizio ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN;

BERNARD SOULIER DISEASE; CHEDIAK HIGASHI SYNDROME; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; GENETIC DISORDER; GLANZMANN DISEASE; HUMAN; ISCHEMIA; MAY HEGGLIN ANOMALY; NEPHROTIC SYNDROME; OCULAR ALBINISM; REVIEW; SCOTT SYNDROME; THROMBOCYTE ANOMALY; THROMBOCYTE RELEASE REACTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPATHY; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME;

BLOOD PLATELETS; GENETIC DISEASES, INBORN; HUMANS; THROMBOCYTOPENIA;

EID: 73449114642     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0078-08     Document Type: Review

References (92)

1. Lopez JA, Andrews RK, Afshar-Kharghan V, et al. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.
2. Bernard J, Soulier JP. Sur une nouvelle variete de dystropfie thrombocytaire-hemorragipare congenitale. Semin Hop Paris 1948; 24 :3217-23.
3. nd ed.).
4. Andrews RK, Shen Y, Gardiner EE, et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82:357-64.
5. Ulsemer P, Strassel C, Baas MJ, et al. Biosynthesis and intracellular post-translational processing of normal and mutant platelet glycoprotein GPIb-IX. Biochem J 2001; 358: 295-303.
6. Afrasiabi A, Lecchi A, Artoni A, et al. Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets 2007; 18: 409-13.
7. Savoia A, Balduini CL, Savino M, et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97: 1330-5.
8. Miller JL, Lyle VA, Cunningham D. Mutation of leucine -57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard Soulier disease. Blood 1992; 79: 439-46.
9. Margaglione M, D'Andrea G, Grandone E, et al. Compound heterozygosity (554-589 del, C515-T transition) in the platelet glycoprotein Ib alpha gene in a patient with a severe bleeding tendency. Thromb Haemost 1999; 81: 486-92.
10. Bernard-Soulier syndrome http://www.bernardsoulier.org/
11. Liang HP, Morel-Kopp MC, Clemetson JM, et al. A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier syndrome (BSS). Thromb Haemost 2005; 94: 599-605.
12. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
13. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005; 31: 150-61.
14. Kahner BN, Shankar H, Murugappan S, et al. Nucleotide receptor signaling in platelets. Thromb Haemost 2006; 4: 2317-26.
15. Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005; 31: 168-73.
16. Cattaneo M, Zinghetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-83.
17. Remijn JA, IJsseldijk MJ, Strunk AL, et al. Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 2007; 45: 187-9.
18. Hayward CP. Inherited disorders of platelet a-granules. Platelets 1997; 8: 197-9.
19. Pujol-Moix N, Hernandez A, Escolar G, et al. Platelet ultrastructural morphometry for diagnosis of partial ä-storage pool disease in patients with mild platelet dysfunction and/or thrombocytopenia of unknown origin. Study of 24 cases. Haematologica 2000; 85: 620-7.
20. Brass LF. The molecular basis for platelet activation. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology. Basic Principles and Practice. New York: Churchill Livingstone; 2000. p.1841-50.
21. Weiss HJ, Witte LD, Kaplan KL, et al. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, betathromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296-319.
22. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007; 21: 21-36.
23. Falik-Zaccai TC, Anikster Y, Rivera CE, et al. A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics. Mol Genet Metab 2001; 74: 303-13.
24. Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med 1984; 143: 261-87.
25. Nurden P, Jandrot-Perrus M, Combrie R, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood 2004; 104: 107-14.
26. Tubman VN, Levine JE, Campagna DR, et al. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood 2007; 109: 3297-9.
27. Diamandis M, Veljkovic DK, Maurer-Spurej E, et al. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrinolysis 2008; 19: 109-19.
28. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-65.
29. Hayward CPM, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87: 4967-78.
30. Oh J, Bailin T, Fukai K, et al. Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet 1996: 14; 300-6.
31. Fukai K, Oh J, Frenk E, et al. Linkage disequilibrium mapping of the gene for Hermansky-Pudlak syndrome to chromosome 10q23.1-q23.3. Human Mol Genet 1995; 4: 1665-9.
32. Gautam R, Chintala S, Li W, et al. The Hermansky-Pudlak syndrome 3 (cocoa) protein is a component of the biogenesis of lysosome-related organelles complex-2 (bloc-2). J Biol Chem 2004; 279: 12935-42.
33. Huizing M, Scher CD, Strovel E, et al. Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res 2002; 51: 150-8.
34. Anderson PD, Huizing M, Claassen DA, et al. Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet 2003; 113: 10-7.
35. Mutations of the Hermansky-Pudlak syndrome-1 gene (HPS1) associated with Hermansky-Pudlak syndrome albinism database. International Albinism Center. University of Minnesota. In: Albinism Datebase Center. University of Minnesota. Available at URL:http://www.cbc.umn.edu/tad/hps1mut.htm.
36. Oh J, Ho L, Ala-Mello S, et al. Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet 1998; 62: 593-8.
37. Corral J, Gonzalez-Conejero R, Pujol-Moix N, et al. Mutation analysis of HPS1, the gene mutated in Hermansky-Pudlak syndrome, in patients with isolated platelet dense-granule deficiency. Haematologica 2004; 89: 325-9.
38. Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15: 22-9.
39. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 1999; 68: 283-303.
40. Jones KL, Stewart RM, Fowler M, et al. Chediak-Higashi lymphoblastoid cell lines: granule characteristics and expression of lysosome-associated membrane proteins. Clin Immunol Immunopathol 1992; 65: 219-26.
41. Certain S, Barrat F, Pastural E, et al. Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome. Blood 2000; 95: 979-83.
42. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet 1996; 14: 307-11.
43. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
44. Braunsteiner H, Pakesch F. Thrombocytoasthenia and thrombocytopathia. Old names and new diseases. Blood 1956; 11: 965-76.
45. Wagner CL, Mascelli MA Neblock DS, et al. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-14.
46. Afrasiabi A, Artoni A, Karimi M, et al. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. Clin Lab Haematol 2005; 27: 324-7. Erratum in: Clin Lab Haematol 2006; 28: 290.
47. D'Andrea G, Margaglione M, Glanzmann's Thrombasthemia Italian Team (GLATIT). Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica 2003; 88: 1378-82.
48. French DL. The molecular genetics of Glanzmann's thrombasthenia. Platelets 1998; 9: 5-20.
49. D'Andrea G, Colaizzo D, Vecchione G, et al. Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost 2002; 87: 1034-42.
50. Springer TA. Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β - propeller domain. Proc Natl Acad Sci USA 1997; 94: 65-72.
51. Bajt ML, Ginsberg MH, Frelinger AL 3rd, et al. A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem 1992; 267: 3789-3.
52. Tozer EC, Liddington RC, Sutcliffe MJ, et al. Ligand binding to integrin aIIb3b is dependent on MIDAS-like domain in the b3 Subunit. J Biol Chem 1996; 271: 21978-84.
53. Bellucci S, Caen J. Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev 2002; 16: 193-202.
54. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol 1994; 31: 312-9.
55. Szakacs G, Langmann T, Ozvegy C, et al. Characterization of the ATPase cycle of human ABCA1: implications for its function as a regulator rather than an active transporter. Biochem Biophys Res Commun 2001; 288: 1258-64.
56. Albrecht C, McVey JH, Elliott JI, et al. A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood 2005; 106: 542-9.
57. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103: 390-8.
58. Thrasher AJ, Bums S, Lorenzi R, Jones GE. The Wiskott-Aldrich syndrome: disordered actin dynamics in haematopoietic cells. Immunol Rev 2000; 178: 118-28.
59. Notarangelo LD, Ochs HD. WAPS and the phenotype range associated with deficiency. Curr Opin Allergy Clin Immunol 2005; 5: 485-90.
60. Imai K, Morio T, Jin Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103: 456-64.
61. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich syndrome protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006; 108: 134-40.
62. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/ genotype correlation. Blood 2004; 104: 4010-9.
63. Zhu QL, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression and phenotype. Blood 1997; 90: 2680-9.
64. Donner M, Schwartz M, Carlsson KU, Holmberg L. Hereditary X-linked thrombocytopenia maps to the same chromosomal region as the Wiskott-Aldrich syndrome. Blood 1988; 72: 1849-53.
65. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nature Genet 1995; 9: 414-7.
66. Savoia A, Dufour C, Locatelli F, et al. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica 2007; 92: 1158-64.
67. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-46.
68. Ballmaier M , Schulze H, Strauss G, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90: 612-9.
69. Strippoli P, Savoia A, Iolascon A, et al. Mutational screening of thrombopoietin receptor (c-mpl) in patients with congenital thrombocytopenia and absent radii (TAR). Br J Haematol 1998; 103: 1633-41.
70. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000; 26: 397-8.
71. Kunishima S, Saito H. Congenital macrothrombocytopenia. Blood Rev 2006; 20: 111-21.
72. Shprintzen RJ, Goldberg RB, Young D, Wolford L. The velo-cardio-facial syndrome: a clinical and genetic analysis. Pediatrics 1981; 67: 167-72.
73. Behrens WE. Mediterranean macrothrombocytopenia. Blood 1975; 46: 199-208.
74. The May-Hegglin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet 2000; 26: 103-5.
75. Najean Y, Lecompte T. Genetic thrombocytopenia with autosomal dominant transmission: a review of 54 cases. Br J Haematol 1990; 74: 203-8.
76. Kato T, Kosaka K, Kimura M, et al. Thrombocytopenia in patients with 22q11.2 deletion syndrome and its association with glycoprotein Ib-β. Genet Med 2003; 5: 113-9.
77. Budarf ML, Konkle BA, Ludlow LB, et al. Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet 1995; 4: 763-6.
78. Kelly RG, Jerome-Majewska LA, Papaioannou VE. The del 22q11.2 candidate gene Tbx1 regulates branchiomeric myogenesis. Hum Mol Genet 2004; 13: 2829-40.
79. Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1997; 90: 698-705.
80. Nurden P, Debili N, Vainchenker W, et al. Impaired megakaryocytopoiesis in type 2B Willebrand disease with severe thrombocytopenia. Blood 2006; 108: 2587-95.
81. Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA 1991; 88: 4761-5.
82. Kunishima S, Kojima T, Tanaka T, et al. Mapping of a gene for May-Hegglin anomaly to chromosome 22q. Human Genet 1999; 105: 379-83.
83. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-45.
84. Arrondel C, Vodovar N, Knebelmann B, et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutation in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002; 13: 65-74.
85. Seri M, Cusano R, Gangarossa S, et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 2000; 26: 103-5.
86. Favier R, Jondeau K, Boutard P, et al. Paris-Trousseau syndrome: clinical, haematological, molecular data of ten new cases. Thromb Haemost 2003; 90: 893-7.
87. Grossfeld PD, Mattina T, Lai Z, et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet 2004; 129: 51-61.
88. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
89. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 2007; 82: 731-5.
90. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004; 9: 317-32.
91. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program 2008; 2008:198-204.
92. Bellucci S, Damaj G, Boval B, et al. Bone marrow transplantation in severe Glanzmann's thromboasthenia with antiplatelet alloimmunization. Bone Marrow Transplant 2000; 25: 327-30.